p53, apoptosis and human cancers

Journal of the Formosan Medical Association

Volumn 95, Issue 7, 1996, Pages 509-522

  Wang, Tzu Hao ^a   Wang, Hsin Shih ^b  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Anticancer therapy; Apoptosis; bax; bcl2; Gene therapy; Mutation; p53; Tumorigenesis

Indexed keywords

APOPTOSIS; HUMAN; MUTATION; NEOPLASM; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; GENES, P53; HUMANS; MUTATION; NEOPLASMS;

EID: 0030184480     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Harris CC: p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1.
2. Wright SC, Zhong J, Larrick JW: Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994;8: 654-60.
3. Preston GA, Lang JE, Maronpot RR, et al: Regulation of apoptosis by low serum in cells of different stages of neoplastic progression: enhanced susceptibility after loss of a senescence gene and decreased susceptibility after loss of a tumor suppressor gene. Cancer Res 1994;54:4214-23.
4. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
5. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992;71:543-6.
6. Crook T, Marston NJ, Sara EA, et al: Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 1994;79:817-27.
7. Kamb A: Sun protection factor p53. Nature 1994;372:730-1.
8. Ziegler A, Jonason AS, Leffell DJ, et al: Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-6.
9. Xia F, Wang X, Wang YH, et al: Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995;55:12-5.
10. Tooze J, ed: Molecular Biology of the Tumor Viruses. New York: Cold Spring Harbor Laboratory Press; 1973:350-403.
11. Chang C, Simmons DT, Martine MA, et al: Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol 1979;31:463-71.
12. Kress M, May E, Cassingena R, et al: Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 1979;31:472-83.
13. Lane DP, Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-3.
14. Linzer DIH, Levine AJ: Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
15. Crawford LV, Pim PC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-6.
16. Oren M, Bienz B, Givol D, et al: Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen. EMBO J 1983;2:1633-9.
17. Pennica D, Goeddel DV, Hayflick JS, et al: The amino acid sequence of murine p53 determined from a cDNA clone. Virology 1984;134:477-83.
18. Harlow E, Williamson NM, Ralston R, et al: Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol 1985;5:1601-10.
19. Jenkins JR, Rudge K, Currie GA: Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 1984;312:651-4.
20. Parada LF, Land H, Weiberg RA, et al: Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984;312:649-51.
21. Hinds P, Finlay C, Levine AJ: Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989;63:739-46.
22. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
23. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
24. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991;351:453-6.
25. Chen PL, Chen Y, Bookstein R, et al: Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990;250:1576-9.
26. Kern SE, Kinzler KW, Bruskin A, et al: Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708-11.
27. Funk WD, Pak DT, Karas RH, et al: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992:12:2866-71.
28. El-Deiry WS, Kern SE, Pietenpol JA, et al: Definition of a consensus binding site for p53. Nature Genet 1992;1:45-9.
29. Vogelstein B, Kinzler K: p53 function and dysfunction. Cell 1992;70:523-6.
30. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
31. Stenger JE, Mayr GA, Mann K, et al: Formation of stable p53 homotetramers and multiples of tetramers. Mol Carcinog 1992;5:102-6.
32. Hainaut P, Hall A, Milner J: Analysis of p53 quarternary structure in relation to sequence-specific DNA binding. Oncogene 1994;9:299-303.
33. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
34. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potent mediator of p53 tumor suppression. Cell 1993;75:817-25.
35. Juven T, Barak Y, Zauberman A, et al: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993;8:3411-6.
36. Kastan M, Zhan Q, El-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
37. Shiio Y, Yamamoto T, Yamaguchi N: Identification of a DNA element that can enhance p53-mediated transactivation. Oncogene 1993;8:2059-65.
38. Zhan Q, Lord KA, Alamo I, et al: The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol 1994;14:2361-71.
39. El-Deiry WS, Harper JW, O'Connor PM, et al: WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
40. Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-62.
41. Sang BC, Chen JY, Minna J, et al: Distinct regions of p53 have a differential role in transcriptional activation and repression functions. Oncogene 1994;9:853-9.
42. Hesketh R: The Oncogene Facts Book. London: Academic Press; 1995:313-22.
43. Seto E, Usheva A, Zambetti GP, et al: Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 1992;89:12028-32.
44. Mack DH, Vartikar J, Pipas JM, et al: Specific repression of TATA-mediated by not initiator-mediated transcription by wild-type p53. Nature 1993;363:281-3.
45. Agoff SN, Hou J, Linzer DIH, et al: Regulation of the human hsp70 promoter by p53. Science 1993;259:84-7.
46. Shiio Y, Yamamoto T, Yamaguchi N: Negative regulation of RB expression by the p53 gene product. Proc Natl Acad Sci USA 1992;89:5206-10.
47. Gannon JV, Greaves R, Iggo R, et al: Activation mutations in p53 produce a common conformational effect, a monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
48. Clore GM, Omichinski JG, Sakaguchi K, et al: High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 1994;265:386-91.
49. Prives C: How loops, β sheets, and α helices help us to understand p53. Cell 1994;78:543-6.
50. Jeffrey PD, Gorina S, Pavletich NP: Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995;267:1498-502.
51. Milner J: Flexibility: the key to p53 function? Trends Biochem Sci 1995;20:49-51.
52. Wu L, Bayle JH, Elenbaas B, et al: Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulates its ability to promote annealing of complementary single strands of nucleic acid. Mol Cell Biol 1995;15:497-504.
53. Jayaraman L, Prives C: Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995;81:1021-9.
54. Lee S, Elenbaas B, Levine A, et al: p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995;81:1013-20.
55. Pavletich NP, Chambers KA, Pabo CO: The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 1993;12:2556-64.
56. Hsu YS, Tang FM, Liu WL, et al: Transcriptional regulation by p53: functional interactions among multiple regulatory domains. J Biol Chem 1995;270:6966-74.
57. Lin J, Chen J, Elenbaas B, et al: Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994;8:1235-46.
58. Lin J, Teresky AK, Levine AJ, et al: Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 1995;10:2387-90.
59. Sabbatini P, Lin J, Levine AJ, et al: Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev 1995;9:2184-92.
60. Benchimol S, Lamb P, Crawford LV, et al: Transformation associated p53 protein is encoded by a gene on human chromosome 17. Somat Cell Mol Genet 1985;11; 505-9.
61. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 1991;253:49-53.
62. Levine AJ, Perry ME, Chang A, et al: The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
63. Lai MY, Chang HC, Li HP, et al: Splicing mutations of the p53 gene in human hepatocellular carcinoma. Cancer Res 1993;53:1653-6.
64. Milner J: DNA damage, p53 and anticancer therapies. Nature Med 1995;1:879-90.
65. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
66. Schwartzman RA, Cidlowski JA: Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr Rev 1993;14:133-51.
67. Compton MM: A biochemical hallmark of apoptosis: internucleosomal degradation of the genome. Cancer Metastasis Rev 1992;11:105-19.
68. Wimalasena J, Cavallo C, Meehan D: Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol Oncol 1991;41:56-63.
69. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
70. Wyllie AH, Morris RG, Smith AL, et al: Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984;142:67-77.
71. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
72. Wijsman JH, Jonker RR, Keijzer R, et al: A new method to detect apoptosis in paraffin section: in situ end-labelling of fragmented DNA. J Histochem Cytochem 1993;41:7-21.
73. Arends MJ, Wyllie AH: Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 1991;32:223-54.
74. Kerr JFR: Definition of apoptosis and overview of its incidence. In: Lavin M, Watters D, eds. Programmed Cell Death. Chur, Switzerland: Harwood Academic Publishers GmbH; 1993:1-15.
75. Cohen GM, Sun XM, Snowden RT, et al: Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J 1992;286:331-4.
76. Oberhammer FA, Pavelka M, Sharma S, et al: Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor b1. Proc Natl Acad Sci USA 1992;89:5408-12.
77. Jacobson MD, Burne JF, Raff MC: Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J 1994;13:1899-910.
78. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
79. Lowe SW, Schmitt EM, Smith SW, et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
80. Lowe SE, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
81. Clarke AR, Prudie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
82. Symonds H, Krall L, Reminton L, et al: p53-dependent apoptosis suppress tumor growth and progression in vivo. Cell 1994;78:703-11.
83. Zhan Q, Fan S, Bae I, et al: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994;9:3743-51.
84. waf1/cip1. Genes Dev 1994;8:2817-30.
85. Raff MC: Social controls on cell survival and cell death. Nature 1992;356:397-400.
86. Lane DP: Cancer, a death in the life of p53. Nature 1993;362:786-7.
87. Caelles C, Helmberg A, Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994;370:220-3.
88. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
89. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
90. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
91. Nunez G, Clarke MF: The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 1994;4:399-403.
92. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74: 609-19.
93. Boise LH, Gonzalez-Garcia M, Postema CE, et al: bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
94. Kozopas KM, Yang T, Buchan HL, et al: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993;90:3516-20.
95. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
96. Chittenden T, Harrington EA, O'Connor R, et al: Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995;374:733-6.
97. Kiefer MC, Brauer MJ, Powers VC, et al: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995;374:736-9.
98. Selvakumaran M, Lin HK, Miyashita T, et al: Immediate early up-regulation of bax expression by p53 but not TGF-b: a paradigm for distinct apoptotic pathways. Oncogene 1994;9:1791-8.
99. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
100. Haldar S, Negrini M, Monne M, et al: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
101. Oltvai AN, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 1994;79:189-92.
102. Yin XM, Oltvai AN, Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3.
103. Knudson CM, Tung KSK, Tourtellotte WG, et al: Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995;270:96-9.
104. Michieli P, Chedid M, Lin D, et al: Induction of WAF1/ CIP1 by a p53-independent pathway. Cancer Res 1994;3391-5.
105. Bressac B, Kew M, Wands J, et al: Selective G to T mutations of p53 gene in hepatocellular carcinoma from South Africa. Nature 1991;350:429-31.
106. 1 induces the transversion of G-T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 1993;90:8586-90.
107. Aguilar F, Harris CC, Sun T, et al: Geographic variation of p53 mutational in nonmalignant human liver. Science 1994;264:1317-9.
108. Sheu JC, Huang GT, Lee PH, et al: Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 1992;52:6098-100.
109. Hosono S, Chou MJ, Lee CS, et al: Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinoma. Oncogene 1993;8:491-6.
110. Eyfjord JE, Thorlacius S, Steinarsdottir M, et al: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 1995;55:646-51.
111. Bardeesy N, Bechwith JB, Pelletier J: Clonal expansion and attenuated apoptosis in Wilm's tumors are associated with p53 gene mutations. Cancer Res 1995;55:215-9.
112. Brash DE, Rudolph JA, Simon JA, et al: A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-8.
113. Li G, Ho VC, Berean K, et al: Ultraviolet radiation induction of squamous cell carcinomas in p53 transgenic mice. Cancer Res 1995;55:2070-4.
114. Graeber TG, Peterson JF, Tsai M, et al: Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14:6264-77.
115. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-91.
116. Kinzler KW, Vogelstein B: Life (and death) in a malignant tumor. Nature 1996;379:19-20.
117. Uchida T, Wada C, Ishida H, et al: p53 mutations and prognosis in bladder tumors. J Urol 1995;153:1097-104.
118. Ng IO, Lei EC, Chan AS, et al: Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995;10:250-5.
119. Hsu HC, Tseng HJ, Lai PL, et al: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 1993;53:4691-4.
120. Crook T, Vousden KH: Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1992;11:3935-40.
121. Thorlacius S, Borrecen AL, Eyfjord JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993;53: 1637-41.
122. Elledge RM, Fuqua SA, Clark GM, et al: Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993;26:225-35.
123. Hamelin R, Laurent-Puig P, Olschwang S, et al: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
124. Uhlman DL, Nguyen PL, Manivel JC, et al: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994;86:1470-5.
125. Simon D, Goretzki PE, Gorelev V, et al: Significance of p53 in human thyroid tumors. World J Surg 1994;18:535-40.
126. Thompson AM, Anderson TJ, Condie A, et al: p53 allele losses, mutations and expression in breast cancer and their relationship to clinicopathological parameters. Int J Cancer 1992;50:528-32.
127. Mulder JW, Baas IO, Polak MM, et al: Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71:1257-62.
128. Dive C, Hickman JA: Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192-6.
129. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metab Rev 1992;11:121-39.
130. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
131. Gottesman MM: Report of a meeting: molecular basis of cancer therapy. J Natl Cancer Inst 1994;86:1277-85.
132. Goyette MC, Cho K, Fasching CL, et al: Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992;12:1387-95.
133. Fujiwara T, Cai DW, Giorges RN, et al: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994;86:1458-62.
134. Takahashi T, Carbone D, Takahashi T, et al: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992;52:2340-3.
135. Yin Y, Tainsky MA, Bischoff FZ, et al: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48.
136. Yonish-Rouach E, Resnitzky D, Lotem J, et al: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
137. Shaw P, Bovey R, Tardy S, et al: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89:4495-9.
138. Wang Y, Ramquist T, Szekely L, et al: Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ 1993;4:467-73.
139. Drazan KE, Shen XD, Csete ME, et al: In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery 1994;116:197-204.
140. Clayman GL, El-Naggar AK, Roth JA, et al: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
141. + p53 conformation. Oncogene 1993;8:2847-51.
142. Lane DP: p53, guardian of the genome. Nature 1992;358:15-20.
143. Stewart BW: Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86:1286-96.
144. Kelly L, Green WF, Hicks GG, et al: Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol Cell Biol 1994;14:4183-92.
145. Borner MM, Myers CE, Sartor O, et al: Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995;55:2122-8.
146. Shimizu T, O'Connor PM, Kohn KW, et al: Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 1995;55:228-31.
147. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
148. Liu Y, Bhalla K, Hill C, et al: Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 1994;48:1265-72.
149. Bhalla K, Ibrado AM, Tourkina E, et al: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-8.
150. Wahl AF, Donaldson KL, Fairchild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996;2:72-9.
151. Zhuang SM, Shvarts A, van Ormondt H, et al: Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 1995;55:486-9.